About Venturemed Group
Venturemed Group is a Healthcare company based in Toledo (United States) founded in 2012. Endovascular devices are developed for PAD and AV fistula treatments. Venturemed Group has raised $51.05 million across 5 funding rounds from investors including Endeavour Vision, RiverVest Venture Partners and S3 Ventures. Its chief executive, as recorded, is Denis Harrington. Venturemed Group offers products and services including FLEX Vessel Prep System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is VentureMed Group, Inc. Its competitors include Avinger, LeMaitre Vascular and Okami Medical; 3 of its 3 listed competitors have raised funding.
Company details
Venturemed Group was founded in 2012 in Toledo, United States, and operates in the medical device sector. Endovascular devices are developed by the company to address peripheral artery disease (PAD) and stenoses in arteriovenous fistulas and grafts. A key product, the FLEX Scoring Catheter, is designed as a single-use device to aid dilation of stenoses, used alongside PTA catheters for lesions in femoral and popliteal arteries.
- Headquarters Toledo, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website venturemedgroup.com
- Social LinkedIn
- Legal Name Venturemed Group, Inc.
- Total Equity Funding$51.05M (USD)
in 5 rounds
- Latest Funding Round$28M (USD), Series C
Oct 2025
- InvestorsEndeavour Vision
& 2 more
Products & Services of Venturemed Group
Venturemed Group offers a comprehensive portfolio of products and services, including FLEX Vessel Prep System.
Device for vessel preparation to improve angioplasty outcomes and reduce trauma.
Funding Insights of Venturemed Group
Venturemed Group has successfully raised a total of $51.05M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $28 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.05M
- Total Rounds 5
- Last Round Series C — $28M
- First Round $15M
(Aug 2017)
- Investors Count 3
All 5 funding rounds of Venturemed Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $28M | Series C | – | S3 Ventures | |
| Oct 2024 | $7M | Series B | – | – | – |
| Nov 2021 | Series B | – | Endeavour Vision, RiverVest Venture Partners | – | |
| Jun 2019 | $1.05M | Series B | – | – | – |
| Aug 2017 | $15M | Series B | – | Endeavour Vision |
3 investors in total: 3 institutional.
Investors in Venturemed Group
Venturemed Group has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Endeavour Vision, RiverVest Venture Partners and S3 Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Endeavour Vision is focused on transformative healthcare technology investments. | endeavourvision.com | Geneva, Switzerland | ||
| rivervest.com | ||||
Venture capital investments are provided to Texas-based startups. | 2005 | s3vc.com | Austin, United States |
Investor details for Venturemed Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Venturemed Group
8 people are tracked at Venturemed Group (5 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Denis Harrington | President & CEO | Leadership |
Jill Schweiger | VP, Clinical, Regulatory & QA | Leadership |
Jenny Zeroni | VP, R&D & Operations | Leadership |
Shelby Hautman | Chief Financial Officer | Leadership |
Dave Michaelson | VP of Sales | Leadership |
Alexander Schmitz | Director | Board & advisors |
J. Robert Paulson | Director | Board & advisors |
Karen Spilizewski | Director | Board & advisors |
Complete people profiles for Venturemed Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Venturemed Group
3 dated milestones of Venturemed Group across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Venturemed Group is founded.
- Funding First funding round of $15.0M.
- Funding Latest funding round, Series C, of $28.0M.
Competitors of Venturemed Group
Venturemed Group has 3 listed competitors in our database, 3 of them funded. They include Avinger, LeMaitre Vascular and Okami Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| avinger.com | 2007 | Redwood, United States | $170.85M | 80 | Provider of image-guided catheter-based products for peripheral artery disease | |
| lemaitre.com | 1983 | Burlington, United States | $4.38M | 317 | Devices for peripheral vascular disease treatment are developed and marketed. | |
| okamimedical.com | 2011 | Aliso Viejo, United States | $62.09M | Innovative medical devices for peripheral vessel treatment are developed. |
Detailed competitors of Venturemed Group
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Venturemed Group
The website of Venturemed Group (venturemedgroup.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 5.7% vs previous month
Websites whose visitors overlap most with Venturemed Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Venturemed Group (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Venturemed Group
Complete news archive for Venturemed Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Venturemed Group
Venturemed Group was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Venturemed Group is headquartered in Toledo, United States. It is registered at Toledo, Ohio, United States.
Denis Harrington is the CEO of Venturemed Group, as recorded in our data.
Venturemed Group is a funded company, having raised a total of $51.05M across 5 funding rounds to date. The company's 1st funding round was a Series B of $15M, raised on Aug 2017.
Venturemed Group was founded in 2012 in Toledo, United States, and operates in the medical device sector. Endovascular devices are developed by the company to address peripheral artery disease (PAD) and stenoses in arteriovenous fistulas and grafts. A key product, the FLEX Scoring Catheter, is designed as a single-use device to aid dilation of stenoses, used alongside PTA catheters for lesions in femoral and popliteal arteries.
Venturemed Group's top competitors include Avinger, Okami Medical and LeMaitre Vascular.
Venturemed Group offers FLEX Vessel Prep System.
Venturemed Group has 3 investors. Key investors include Endeavour Vision, RiverVest Venture Partners, and S3 Ventures.
Venturemed Group operates through Venturemed Group, Inc..